FOIA to Health and Human Services seeking communications of Arina Grossu and Rob Weaver regarding rallies protesting the results of the 2020 election. Grossu and Weaver organized a December 2020 rally that was a precursor to the events of Jan. 6.

Former White House adviser Stephen Miller spearheaded the Trump administration’s 2020 effort to expel undocumented migrants at the border under the guise of fighting the pandemic, emails obtained by American Oversight suggest.

U.S. Centers for Disease Control and Prevention from the U.S. Department of Health and Human Services in response to American Oversight's request for communications with Stephen Miller and directives from the White House regarding immigration restrictions during the coronavirus pandemic.

Records from the U.S. Department of Health and Human Services in response to American Oversight's request for text messages of high-ranking officials at the Food and Drug Administration regarding the coronavirus pandemic.

Records released by the Department of Health and Human Resources in response to American Oversight’s request for records reflecting whether the coronavirus is or could be “airborne,” from on or before Feb. 7, 2020

FOIA request to the U.S. Food and Drug Administration seeking communications sent by senior FDA officials to external entities regarding Aduhelm (aducanumab), an Alzheimer's drug produced by Biogen.

FOIA request to the U.S. Food and Drug Administration seeking communications sent by Peripheral and Central Nervous System Drugs Advisory Committee members regarding Aduhelm (aducanumab), an Alzheimer's drug produced by Biogen.

FOIA request to the U.S. Food and Drug Administration seeking any final analyses or assessments used by FDA during deliberations over the approval of Aduhelm (aducanumab), an Alzheimer's drug produced by Biogen.

FOIA request to the U.S. Department of Health and Human Services' Office of Inspector General seeking any final documents produced by OIG during its investigation into the FDA's approval of Aduhelm, and into interactions between Biogen and the FDA, leading up to the drug's approval.